.S. Securities and Exchange Commission and in
Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in each of the provinces of
Canada. The offering is being made only by means of a prospectus supplement and accompanying final short form base shelf prospectus. Copies of the prospectus relating to this offering, when available, may be obtained by contacting Deutsche Bank Securities Inc., Attention: Prospectus Department, Harborside Financial Center, 100 Plaza One,
Jersey City, New Jersey 07311-3988, telephone: 1-800-503-4611.
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Labopharm Inc.
Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. Its second product, OLEPTRO(TM), a novel formulation of trazodone for the treatment of major depressive disorder in adults, has received regulatory approval in the U.S. and is under regulatory review in Canada. Labopharm has initiated the European regulatory approval process for its third product, a twice-daily formulation of
'/>"/>
SOURCE Labopharm Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine news :1.
Labopharm settles $1 million draw down under standby equity distribution agreement2.
Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe3.
Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement4.
Labopharm Reports Results for Third Quarter Fiscal 20095.
Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings6.
Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission7.
Labopharm submits response to FDA for novel antidepressant8.
Labopharm Reports Results for Second Quarter Fiscal 20099.
Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference10.
Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)11.
Labopharm receives complete response letter from the U.S. FDA for novel antidepressant